Ajanta Pharma reports pledge of 10.07 lakh shares by Aayush Agrawal Trust

What Ajanta Pharma announced

Ajanta Pharma Ltd. (BSE: 532331, NSE: AJANTPHARM) disclosed that Aayush Agrawal Trust, acting through its trustee Mr. Aayush Agrawal, and Mr. Aayush Agrawal in his individual capacity have created a pledge over 10,06,726 equity shares of the company. The pledge is intended as collateral for a new loan. The filing was submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on 3 July 2026.

Details of the pledge

• Shares pledged: 10,06,726 shares (approximately 10.07 lakh shares).
• Percentage of total share capital: 0.78 % (as shown in the promoter‑wise table).
• Date of creation: 30 June 2026.
• Purpose: Securing a new loan, as stated in the disclosure.
• Promoters involved:
  • Aayush Agrawal Trust (trustee: Mr. Aayush Agrawal)
  • Mr. Aayush Agrawal (individual capacity)

The filing also lists other members of the Agrawal family and related trusts, but only the Aayush Agrawal entities reported a pledge. No loan amount, lender name, or terms of the loan were disclosed.

Regulatory framework

The disclosure is made under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 (SAST). These provisions require promoters, persons acting in concert (PACs), or any other party acquiring a substantial shareholding to report the creation, release, or invocation of any encumbrance (such as a pledge) on the shares. The filing includes the prescribed form, detailing the number of shares, percentage of capital, type of encumbrance, and the reason for the pledge.

Key facts at a glance

Why this matters for investors

The creation of a pledge over a promoter’s shares introduces a financial encumbrance on the underlying equity. While the pledged shares remain part of the promoter’s holding, they can be seized or sold by the lender if the loan defaults, potentially affecting the promoter’s voting power and the company’s share‑holding pattern. For minority shareholders, a higher concentration of pledged shares may signal increased financial leverage among promoters, which could influence corporate governance dynamics. However, the pledged amount in this case is modest—under 1 % of the total share capital—so the immediate impact on control is limited.

Investors should monitor any subsequent disclosures that may indicate release, invocation, or additional pledges, as well as any material changes in the loan terms that could affect the promoter’s ability to retain the pledged shares.

Conclusion

Ajanta Pharma has formally reported that Aayush Agrawal Trust and Mr. Aayush Agrawal pledged 10,06,726 shares, representing 0.78 % of the company’s equity, to secure a new loan. The disclosure complies with SEBI’s SAST regulations and was filed on 3 July 2026. No further details on the loan amount or lender were provided, and no other promoters reported similar encumbrances. Future filings may reveal whether the pledge is released or additional shares are pledged.

"The pledge was created on 30 June 2026 for a new loan and reported under SEBI (SAST) Regulations."